Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Brendan P. Eckelman(Ambrx (United States))
Cited by 40
Related Papers
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
|EMBO Reports|2006|815
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
|Cancer Discovery|2023|115
Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
|Clinical Cancer Research|2020|29